Effects of estrogen receptor expression on growth and transformation of cells overexpressing neu

Russell, Kerry S.; Lee, E; Kiyokawa, Nobutaka; Saya, Hideyuki; Hung, Ming-Chun

doi:10.3892/or.3.3.433

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study provided evidence that the inverse clinical correlation between ErbB2 and ER expression may partially be due to transcriptional repression of erbB2 by E2/ER. In addition, the growth rate of ER + /ErbB2-overexpressing breast cancer cells was stimulated by E2 but the transformation phenotype was inhibited by E2, most likely due to downregulation of p185 ErbB2 (Russell et al, 1996). ER + breast cancer patients are frequently treated with estrogen antagonists such as TAM.…”

Section: Hormone Therapymentioning

confidence: 99%

Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

2000

View full text Add to dashboard Cite

This past decade has witnessed the remarkable advances in the understanding of the role of the erbB2 gene in cancers and the stunning progress in developing targeted therapies for erbB2-overexpressing cancers. Activation of the ErbB2 receptor signaling pathways can enhance various metastasis-associated properties that lead to an increase of cancer metastasis. Additionally, ErbB2 overexpression confers therapeutic resistance via receptor-mediated antiapoptotic signals. To limit these disastrous e ects of the overexpressed ErbB2, various ErbB2-blocking strategies have been developed in the laboratories and several have been tested in clinical trials or approved as therapies for ErbB2 overexpressing cancers. In this article, we will discuss the detrimental e ects of the erbB2 gene in cancers, with a focus on breast cancer. We will also outline ErbB2-targeting strategies as potential therapies for ErbB2-overexpressing cancers. Progress in understanding the molecular biology of ErbB2 and in molecular-based treatment of ErbB2-overexpressing tumors will bring great bene®ts to cancer patients. Oncogene (2000) 19, 6115 ± 6121.

show abstract

Section: Hormone Therapymentioning

confidence: 99%